vimarsana.com

Latest Breaking News On - Sino biologics chief executive yu xuefeng - Page 1 : vimarsana.com

China s CanSino Confident Its mRNA COVID Vaccine as Good as Moderna, Pfizer Shots

CanSino Biologics Chief Executive Yu Xuefeng said on Friday he was confident his company s experimental COVID-19 vaccine using messenger RNA (mRNA) technology was as good as shots from Moderna and Pfizer-BioNTech.

Health News Roundup: U S FDA says India-made eye drop linked to some infections, blindness and one death; China records 3,278 COVID-related deaths between Jan 27 and Feb 2 and more

The Biden administration in June dropped its requirement that people arriving in the country by air must test negative for COVID-19 but has not lifted Centers for Disease Control and Prevention (CDC) vaccination requirements. Gilead's breast cancer drug gets U.S. FDA approval for third indication Gilead Sciences said on Friday the U.S. Food and Drug Administration had greenlighted the use of Trodelvy for a third indication, providing another treatment option for patients with the most common type of breast cancer.

Health News Roundup: Canada moves to extend exclusion of mental illness from assisted death; China s CanSino confident its mRNA COVID vaccine as good as Moderna, Pfizer shots and more

The drug was approved for an advanced form of breast cancer with a subtype known as HR-positive/HER2-negative in patients, who had stopped responding to a hormone-based therapy and at least two earlier systemic therapies. India to spend $79.6 million to strengthen drug regulatory system India will spend $79.6 million on strengthening its drug regulatory system, the health minister said on Friday, after the World Health Organization raised concerns about domestically produced cough syrups being linked to the death of 89 children in two countries.

Reuters Health News Summary

The Biden administration in June dropped its requirement that people arriving in the country by air must test negative for COVID-19 but has not lifted Centers for Disease Control and Prevention (CDC) vaccination requirements. Gilead's breast cancer drug gets U.S. FDA approval for third indication Gilead Sciences said on Friday the U.S. Food and Drug Administration had greenlighted the use of Trodelvy for a third indication, providing another treatment option for patients with the most common type of breast cancer.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.